Urolog. pro Praxi, 2006; 5: 210-213

PHARMACOTHERAPY OF BENIGN PROSTATIC HYPERPLASIA, PREVENTION, EFFECTIVE MEDICATIONS, ADVERSE EVENTS

MUDr. Miloš Broďák, MUDr. Lukáš Holub
Urologická klinika FN a LF UK Hradec Králové

Benign prostatic hyperplasia is common disease of aging men. The therapy has made great improvements in the last the fifteen years. The most common mode of treatment is pharmacotherapy. The most effective drugs are alpha 1-adrenergic blockers and 5-alpha reductase inhibitors, possibly a combination of these drugs. The authors describe current pharmacotherapy, its efficacy and adverse events.

Keywords: Key words: benign prostatic hyperplasia, pharmacotherapy, phytotherapy, alpha-blocker, 5-alpha-reductase inhibitor.

Published: January 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Broďák M, Holub L. PHARMACOTHERAPY OF BENIGN PROSTATIC HYPERPLASIA, PREVENTION, EFFECTIVE MEDICATIONS, ADVERSE EVENTS. Urol. praxi. 2006;7(5):210-213.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Arrighi HM, Metter EJ, Guess HA et al. Natural history of benign prostatic hyperplasia and risk of prostatectomy the Baltimore Longitudinal Study of Aging. Urology 1991; 35: 4-8. Go to original source... Go to PubMed...
    2. Cancer Facts: Chemoprevention. Bethseda, MD: National Cancer Institute 2002.
    3. Debruyne F, Barkin J, van Erps P et al. Efficacy and safety of long-term treatment with dual 5 alpha- reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 2004; 46: 488-495. Go to original source... Go to PubMed...
    4. Djavan B, Chapple C, Milani S, Marberger M. State of the art on the efficacy and tolerability of alpha 1-adrenoreceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2004; 64: 1081-1088. Go to original source... Go to PubMed...
    5. Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha 1-adrenoreceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Eur Urol 1999; 36: 1-13. Go to original source... Go to PubMed...
    6. Hora M. Fytopreparáty v léčbě BHP. Urol Listy 2004; 4: 42-45.
    7. Chapple C, Batista JE, Berges R et al. The impact of nocturia in patients with LUTS/BHP: Need for new recommendations. EurUrol 2006; 5 (1): 12-18. Go to original source...
    8. Chute CG, Panser LA, Girman CJ et al. The prevalence of prostatism: a population based survey of urinary symptoms. J Urol 1993; 150: 85-89. Go to original source... Go to PubMed...
    9. Klein EA, Thompson IM, Lippman SM et al. SELECT: the selenium and vitamin E cancer prevention trial. Urol Oncol 2003; 21: 59-65. Go to original source... Go to PubMed...
    10. Lukeš M, Záleský M, Urban M. Nové trendy v konzervativní léčbě benigní hyperplasie prostaty. Urolog pro Praxi 2006; 1: 12-14.
    11. MacDonald JD, Roehrborn CG, Bautista OM et al. Afluzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia" a systematic review of efficacy and adverse effects. Urology 2005; 66 (4): 780-788. Go to original source... Go to PubMed...
    12. Madersbacher S, Alivizatos G, Nordling J et al. EAU 2004 Guidelines on Assessment, Therapy and Follow-Up of Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction (BPH Guidelines). Eur Urol 2004; 46: 547-554. Go to original source... Go to PubMed...
    13. Marberger M, Harkaway R, de la Rosette J. Optimizing the medical management of benign prostatic hyperplasia. Eur Urol 2004; 45: 411-419. Go to original source... Go to PubMed...
    14. Navrátil P. Uroselektivita afluzosinu při léčbě pacientů se symptomy BPH. Čes Urol 2001; 2: 4-8.
    15. Novara G, Galfano A, Berto RB et al. Inflammation, apoptosis, and BPH: What is the Evidence? Eur Urol 2006; 5 (Suppl): 401-408. Go to original source...
    16. Pavlík I, Dvořáček J. Alfablokátory v léčbě BHP. Urol Listy 2004; 4: 35-37.
    17. Schraml J. Role a místo inhibitorů 5-alfa-reduktázy v léčbě benigní hyperplasie prostaty. Urol Listy 2004; 4: 39-41.
    18. Tavani A, Longoni E, Bosetti C et al. Intake of selected micronutrients and the risk of surgically treated benign prostatic hyperplasia: a case-control study from Italy. Eur Urol 2006; 50: 549-554. Go to original source... Go to PubMed...
    19. Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 293-295. Go to original source... Go to PubMed...
    20. Yang XJ, Leckesll K, Short K et al. Does long-term finasteride therapy affect the histological features of benign prostatic tissue and prostate cancer on needle biopsy? Urology 1999; 53: 696-700. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.